Cipla Ltd

Cipla has allotted 17,915 equity shares under ESOS on 14 May 2026. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,56,01,092 comprising of 80,78,00,546 equity shares of face value Rs 2 each.

Cipla announced that the 90th Annual General Meeting(AGM) of the company will be held on 25 June 2026.

Net profit of Cipla declined 54.61% to Rs 554.64 crore in the quarter ended March 2026 as against Rs 1221.84 crore during the previous quarter ended March 2025. Sales declined 2.02% to Rs 6464.26 crore in the quarter ended March 2026 as against Rs 6597.72 crore during the previous quarter ended March 2025. For the full year,net profit declined 26.43% to Rs 3879.23 crore in the year ended March 2026 as against Rs 5272.52 crore during the previous year ended March 2025. Sales rose 2.09% to Rs 27711.69 crore in the year ended March 2026 as against Rs 27145.40 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales6464.266597.72 -2 27711.6927145.40 2 OPM %14.7723.30 -21.2326.26 - PBDT1089.981813.03 -40 6710.527927.76 -15 PBT707.061504.30 -53 5499.546820.81 -19 NP554.641221.84 -55 3879.235272.52 -26 Powered by Capital Market - Live

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2026, inter alia, have recommended the final dividend of Rs 13 per equity Share (i.e. 650%) , subject to the approval of the shareholders.

Revenue from operations declined 2.02% YoY to Rs 6,464.26 crore in Q4 FY26 from Rs 6,597.72 crore in the year-ago period. Revenue fell 7.16% sequentially from Rs 6,962.97 crore in Q3 FY26. EBITDA fell 35.18% YoY to Rs 997 crore in Q4 FY26. EBITDA margin stood at 15.2% in Q4 FY26 lower than 22.8% in Q4 FY25. Profit before tax stood at Rs 707.06 crore in Q4 FY26, down 53% from Rs 1,504.30 crore in Q4 FY25 and declined 20.83% from Rs 893.11 crore in Q3 FY26. On the cost front, total expenditure increased 8.48% YoY to Rs 5,982.30 crore in Q4 FY26 from Rs 5,514.85 crore in Q4 FY25. Raw material cost declined 1.13% YoY to Rs 1,382.15 crore from Rs 1,397.94 crore. However, employee expenses rose 14.69% to Rs 1,414.25 crore from Rs 1,233.10 crore. Interest cost declined 6.35% YoY to Rs 13.13 crore from Rs 14.02 crore, while depreciation expense increased 24.03% to Rs 382.92 crore from Rs 308.73 crore. The company recognised an exceptional charge of around Rs 275.91 crore in Q3 FY26 towards higher gratuity and leave liabilities arising from the implementation of the new Labour Codes notified by the Government of India. The impact was primarily due to changes in the definition of wages for employees and contract labour. India business revenue grew 15% YoY to Rs 3,007 crore in Q4 FY26, supported by double-digit growth across branded prescription, trade generics and consumer health businesses. North America revenue declined 26% YoY to Rs 1,414 crore during the quarter, while One Africa revenue rose 21% to Rs 1,236 crore. Emerging Markets and Europe revenue fell 9% to Rs 819 crore. R&D investments stood at Rs 509 crore during the quarter, representing 7.8% of sales. The company reported a strong net cash position of Rs 10,526 crore as of Q4 FY26. For FY26, revenue from operations rose 2.09% YoY to Rs 27,711.69 crore from Rs 27,145.40 crore in FY25. Profit before tax declined 23.42% to Rs 5,223.63 crore from Rs 6,820.81 crore, while profit after tax fell 26.43% to Rs 3,879.23 crore from Rs 5,272.52 crore. EBITDA fell 16.88% YoY to Rs 5,925 crore in Q4 FY26. EBITDA margin stood at 21% in Q4 FY26 lower than 25.9% in Q4 FY25. Net cash from operating activities declined to Rs 3,940.02 crore in FY26 from Rs 5,004.98 crore in FY25. Achin Gupta, MD and global CEO of Cipla, said the company recorded its highest-ever annual revenue of Rs 28,163 crore in FY26 despite near-term challenges in certain markets. He added that the India business crossed the Rs 12,500 crore annual revenue milestone, while the company remains focused on expanding key markets, strengthening flagship brands and investing in future product pipelines. Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets. Shares of Cipla were up 3.93% at Rs 1342.80 on the BSE. Powered by Capital Market - Live

The board of Cipla at its meeting held on 13 May 2026 has approved the appointment of Sushrut Kulkarni as President & Global Chief - Integrated Product Development (IPD), member of Management Council and Senior Management Personnel (SMP) of the Company w.e.f. 18 May 2026.

Cipla Ltd is up for a third straight session in a row. The stock is quoting at Rs 1288.9, up 4.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.75% on the day, quoting at 24195.15. The Sensex is at 77763.49, down 0.96%. Cipla Ltd has risen around 5.7% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 30.64 lakh shares today, compared to the daily average of 18.9 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 1286.8, up 3.91% on the day. Cipla Ltd is down 16.94% in last one year as compared to a 0.21% drop in NIFTY and a 4.48% drop in the Nifty Pharma index.The PE of the stock is 21.77 based on TTM earnings ending December 25.

The approval covers a product that is the first AB-rated generic therapeutic equivalent of Ventolin HFA, originally marketed by GlaxoSmithKline. The drug is indicated for the treatment or prevention of bronchospasm in adults and children aged four years and above with reversible obstructive airway disease. It is also used to prevent exercise-induced bronchospasm in patients in the same age group. Cipla said the approval strengthens its respiratory portfolio in the U.S. market. The company already has approved generics for both Ventolin HFA and Proventil HFA. According to data from IQVIA, the total U.S. market for albuterol inhalers is estimated at around $1.5 billion. The development is seen as a positive for Cipla's U.S. business, particularly in the respiratory segment, where the company continues to expand its presence with a differentiated portfolio. Commenting on the approval, Achin Gupta, Managing Director & Global CEO, Cipla, said: 'This marks an important milestone for Cipla and reflects our strong scientific and regulatory capabilities in complex inhalation products. Lung health remains at the heart of all our offerings and follows a singular, distilled objective, to build a sustainable and differentiated portfolio for patients globally.' Marc Falkin, Chief Executive Officer, Cipla North America, added: 'Strengthening our U.S. respiratory franchise, the product will be manufactured at our newly constructed, dedicated inhalation facility in Fall River, Massachusetts, reinforcing both supply resilience and our domestic manufacturing footprint. With planned volume ramp-up, we expect to drive meaningful difference in the lives of patients.' Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. The company reported 56.96% decrease in consolidated net profit to Rs 675.80 crore in Q3 FY26 as against Rs 1,570.51 crore in Q3 FY25. Total revenue from operations marginally rose 0.02% YoY to Rs 7,074.48 crore in Q3 FY26.

The inspection was a routine current good manufacturing practices (cGMP) inspection and a pre-approval inspection (PAI). On conclusion of the inspection, the Company received two inspectional observations in Form 483. The company will work closely with the US FDA and is committed to address these comprehensively within stipulated time,' Cipla said in a statement. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. The company reported 56.96% decrease in consolidated net profit to Rs 675.80 crore in Q3 FY26 as against Rs 1,570.51 crore in Q3 FY25. Total revenue from operations marginally rose 0.02% YoY to Rs 7,074.48 crore in Q3 FY26. The scrip had added 0.61% to end at Rs 1238.30 on the BSE on Friday.

Cipla announced that that the USFDA has conducted an inspection at the Company's manufacturing facility in Verna, Goa from 6 to 17 April 2026. The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI). On conclusion of the inspection, the Company received two (2) inspectional observations in Form 483.